This case study takes a look at pharmaceutical reimbursement in the U.S. and the UK using Gilead’s Hepatitis C drug, Sovaldi as an example of how the two different countries operate. What lessons can the U.S. learn from other countries like the UK on issues like value and pricing in the pharmaceutical industry? Read more here. (Source: Context Matters, 2/3/16)
You are here: / / What Can the US Learn from the EU on Reimbursement and Pricing?